<DOC>
	<DOCNO>NCT00035035</DOCNO>
	<brief_summary>Definition : This study compare drug GEMZAR combination GEMZAR plus ALIMTA treatment cancer pancreas . Patients may able participate study cancer pancreas remove surgery OR spread new site body .</brief_summary>
	<brief_title>A Phase 3 Trial ALIMTA ( LY231514 , Pemetrexed ) Plus GEMZAR Versus GEMZAR Patients With Unresectable Metastatic Cancer Pancreas .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Pancreas cancer remove surgery OR spread new site body . You must one tumor physically measure scanned doctor . You chemotherapy , immunotherapy , biologic therapy , hormonal therapy pancreas cancer , include 5FU . You radiation 4 week start study , radiation whole pelvis . Treatment medication device approve regulatory agency , like FDA , time enter study . Documentation cancer spread brain . Pregnant breastfeeding . A second primary cancer . Unable stop aspirin nonsteroidal antiinflammatory agent ( like ibuprofen ) 58 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Unresectable Metastatic Cancer Pancreas</keyword>
	<keyword>Alimta</keyword>
</DOC>